About
Rare Muscle Disorders
Areas of Focus
Categories
Biologics & BiopharmaceuticalSmall Molecule PharmaceuticalBoston & New England
Team (10)
Alpna Seth, Ph.D.
Alpna Seth, Ph.D.
Keros Therapeutics
team_member
Carl L. Gordon, Ph.D., C.F.A.
Carl L. Gordon, Ph.D., C.F.A.
Keros Therapeutics
team_member
Esther Cho, J.D.
Esther Cho, J.D.Senior Vice President,General Counsel
Keros Therapeutics
executive
Jasbir Seehra, Ph.D.
Jasbir Seehra, Ph.D.President, Chief Executive Officer and Director
Keros Therapeutics
executive
Jean-Jacques Bienaimé, M.B.A.
Jean-Jacques Bienaimé, M.B.A.Chairman
Keros Therapeutics
board_chair
Julius Knowles, M.B.A.
Julius Knowles, M.B.A.
Keros Therapeutics
team_member
Clinical Trials (3)
View allTotal Trials
3
As Lead Sponsor
3
As Collaborator
0
Total Enrollment
159
By Phase
PHASE1: 1PHASE2: 2
By Status
COMPLETED: 2WITHDRAWN: 1
Clinical Trials Pipeline3 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2022
2023
2024
2025
2026
2027
Today
Hover over trial bars to see details
Recent Trials
NCT06147921Lead Sponsor
Phase 1, SAD/MAD of Verasone™ Administered by Sinonasal Irrigation in Healthy Participants
PHASE1Completed
46 participants
Started: Dec 15, 2023 · Completed: Dec 13, 2024
NCT05927012Lead Sponsor
A Study to Evaluate the Safety and Preliminary Efficacy of a Response-guided Dose Titration of KER-047 in the Treatment of Functional IDA (Iron Deficiency Anemia).
PHASE2Withdrawn
Started: Nov 30, 2023 · Completed: Jan 4, 2026
NCT05975905Lead Sponsor
A Study to Investigate the Safety and Efficacy of KER-012 in Combination With Background Therapy in Adult Participants With Pulmonary Arterial Hypertension (PAH) (TROPOS Study).
PHASE2Completed
113 participants
Started: Oct 17, 2023 · Completed: Mar 11, 2025
Locations (1)
Headquarters
Lexington, MA, United States
Map
Loading map...